NASDAQ:ADTX Aditxt (ADTX) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ADTX Stock Alerts $2.30 -0.17 (-6.88%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$2.28▼$2.4050-Day Range$2.22▼$3.9552-Week Range$2.14▼$68.08Volume44,596 shsAverage Volume75,837 shsMarket Capitalization$552,000.00P/E RatioN/ADividend YieldN/APrice Target$61.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aditxt alerts: Email Address Aditxt MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,552.2% Upside$61.00 Price TargetShort InterestBearish10.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.23 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAditxt has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAditxt has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.83% of the float of Aditxt has been sold short.Short Interest Ratio / Days to CoverAditxt has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aditxt has recently increased by 988.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAditxt does not currently pay a dividend.Dividend GrowthAditxt does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADTX. Previous Next 1.8 News and Social Media Coverage News SentimentAditxt has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aditxt this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for ADTX on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aditxt insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.23% of the stock of Aditxt is held by insiders.Percentage Held by InstitutionsOnly 15.54% of the stock of Aditxt is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioAditxt has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Aditxt Stock (NASDAQ:ADTX)Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Read More ADTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADTX Stock News HeadlinesMay 5, 2024 | investing.comAditxt secures $4.2 million in private placementMay 3, 2024 | finance.yahoo.comCORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesMay 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 3, 2024 | businesswire.comAditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq RulesApril 26, 2024 | americanbankingnews.comShort Interest in Aditxt, Inc. (NASDAQ:ADTX) Increases By 988.7%April 2, 2024 | marketwatch.comAditxt to Buy Biopharmaceutical Company Appili Therapeutics for Undisclosed AmountApril 2, 2024 | markets.businessinsider.comAppili Therapeutics To Be Acquired By AditxtApril 2, 2024 | businesswire.comAditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)May 5, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.March 27, 2024 | finanznachrichten.deEvofem Biosciences, Inc.: Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023March 27, 2024 | prnewswire.comEvofem Reports $18.2 million of Phexxi Net Product Sales in 2023March 20, 2024 | prnewswire.comEvofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-CalMarch 7, 2024 | prnewswire.comFor Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended PregnancyFebruary 10, 2024 | markets.businessinsider.comAditxt CEO Provides Short-Term Loan to Bolster StabilityFebruary 10, 2024 | msn.comAditxt, Inc. Enters New Financial Obligation Impacting InvestorsFebruary 3, 2024 | msn.comAditxt Announces Merger Agreement with Evofem BiosciencesJanuary 30, 2024 | msn.comAditxt buys Brain Scientific's portfolio of EEG brain monitoring technologies and devicesJanuary 30, 2024 | finance.yahoo.comAditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology ApplicationsJanuary 18, 2024 | msn.comAditxt files to sell 3.79M shares for holdersJanuary 14, 2024 | benzinga.comAditxt Stock (NASDAQ:ADTX), Short Interest ReportJanuary 13, 2024 | benzinga.comAditxt Stock (NASDAQ:ADTX) Dividends: History, Yield and DatesJanuary 8, 2024 | finance.yahoo.comAditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 MillionJanuary 5, 2024 | finance.yahoo.comAditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq RulesJanuary 3, 2024 | bizjournals.comRichmond's Aditxt reaches deal to acquire maker of PhexxiJanuary 3, 2024 | marketwatch.comAditxt Shares Drop 24% After Pricing of Private PlacementJanuary 2, 2024 | finance.yahoo.comAditxt, Inc. Regains Compliance with Nasdaq Stockholders’ Equity RequirementDecember 29, 2023 | finance.yahoo.comAditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq RulesSee More Headlines Receive ADTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aditxt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today5/05/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADTX CUSIPN/A CIK1726711 Webwww.aditxt.com Phone650-870-1200FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$61.00 High Stock Price Target$61.00 Low Stock Price Target$61.00 Potential Upside/Downside+2,552.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,380,000.00 Net Margins-5,016.31% Pretax Margin-5,021.71% Return on Equity-1,614.64% Return on Assets-191.28% Debt Debt-to-Equity RatioN/A Current Ratio0.27 Quick Ratio0.24 Sales & Book Value Annual Sales$640,000.00 Price / Sales0.86 Cash FlowN/A Price / Cash FlowN/A Book Value$67.18 per share Price / Book0.03Miscellaneous Outstanding Shares240,000Free Float236,000Market Cap$552,000.00 OptionableNo Data Beta1.35 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Amro A. Albanna (Age 54)Co-Founder, Chairman & CEO Comp: $472.12kDr. Shahrokh Shabahang D.D.S. (Age 61)M.S., Ph.D., Co-Founder, Chief Innovation Officer, Secretary & Director Comp: $323.5kMr. Thomas J. Farley CPA (Age 51)Chief Financial Officer Comp: $357.89kMs. Corinne D. Pankovcin CPA (Age 58)M.B.A., Chief Commercialization Officer Comp: $366.77kMs. Rowena Albanna (Age 58)Chief Operating Officer Ms. Jennifer LeeDirector of Human ResourcesDr. Dolly B. Tyan Ph.D.Senior Vice President of Clinical Development TransplantationMr. Ge Chen M.D.M.S., Senior Vice President of Preclinical Research & DiscoveryMore ExecutivesKey CompetitorsChina SXT PharmaceuticalsNASDAQ:SXTCBellerophon TherapeuticsNASDAQ:BLPHEvofem BiosciencesNASDAQ:EVFMAthersysNASDAQ:ATHXAptevo TherapeuticsNASDAQ:APVOView All CompetitorsInsidersParibas Securities Corp BnpSold 20,800 sharesTotal: $691,184.00 ($33.23/share)View All Insider Transactions ADTX Stock Analysis - Frequently Asked Questions Should I buy or sell Aditxt stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aditxt in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ADTX shares. View ADTX analyst ratings or view top-rated stocks. What is Aditxt's stock price target for 2024? 1 brokers have issued 1 year price objectives for Aditxt's stock. Their ADTX share price targets range from $61.00 to $61.00. On average, they expect the company's share price to reach $61.00 in the next year. This suggests a possible upside of 2,552.2% from the stock's current price. View analysts price targets for ADTX or view top-rated stocks among Wall Street analysts. How have ADTX shares performed in 2024? Aditxt's stock was trading at $6.63 at the beginning of the year. Since then, ADTX shares have decreased by 65.3% and is now trading at $2.30. View the best growth stocks for 2024 here. Are investors shorting Aditxt? Aditxt saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 212,300 shares, an increase of 988.7% from the March 31st total of 19,500 shares. Based on an average trading volume of 361,100 shares, the days-to-cover ratio is presently 0.6 days. Approximately 10.8% of the shares of the company are short sold. View Aditxt's Short Interest. When is Aditxt's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ADTX earnings forecast. How were Aditxt's earnings last quarter? Aditxt, Inc. (NASDAQ:ADTX) released its quarterly earnings results on Wednesday, August, 11th. The company reported ($840.00) earnings per share for the quarter, missing analysts' consensus estimates of ($100.00) by $740.00. Aditxt had a negative net margin of 5,016.31% and a negative trailing twelve-month return on equity of 1,614.64%. When did Aditxt's stock split? Aditxt's stock reverse split on the morning of Friday, August 18th 2023. The 1-40 reverse split was announced on Friday, August 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Aditxt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aditxt investors own include Tesla (TSLA), Dynavax Technologies (DVAX), Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Block (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS). Who are Aditxt's major shareholders? Aditxt's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amro A Albanna, Corinne Pankovcin, Paribas Securities Corp Bnp, Shahrokh Shabahang and Thomas J Farley. View institutional ownership trends. How do I buy shares of Aditxt? Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADTX) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
